Clinical Trial Update: RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of RO4929097 in recurrent/metastatic epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer has completed and results hav…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• RO4929097 (RO4929097)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2017-05-24